⌕
Ideaya Biosciences · IDYA · Nasdaq
Tenet 57 · Mixed
Compare
$30.36−4.62%At closeTenet 57 · Mixed
$30.36−1.47 (−4.62%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Ideaya Biosciences (IDYA) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~67.3%/yr (FY21→FY25), net margin −52.0%. Worth your attention in FY25: Share count (+151.0%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲3024.4%
218.7
FY21→FY25CAGR +67.3%/yr
Net income ($M)▲58.6%
−113.7
FY21→FY25CAGR —
Free cash flow ($M)▲70.8%
−73.5
FY21→FY25CAGR —
Diluted EPS▲61.9%
−1.28
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+151.0%

35.3mn → 88.5mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$2.4M

−38.6% YoY in FY25 · 1.1% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)218.7Revenue0.0COGS218.7Gross profit−314.7R&D−63.3SG&A−159.3Op income45.6Tax & other−113.7Net income

-52¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~4%FY21FY25

Over this window: gross 100.0% → 100.0%. Net margin -52.0% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
36,535.0218,710.07,000.023,385.050,931.027,941.0▲3024.4%+67.3%
Cost of revenue
—0.00.00.00.00.0——
Gross profit
36,535.0218,710.07,000.023,385.050,931.027,941.0▲3024.4%+67.3%
Research & development
412,590.0314,704.0294,673.0129,508.089,536.058,158.0▲6.8%+52.5%
Selling, general & admin
86,982.063,319.039,302.028,306.023,897.020,051.0▲61.1%+33.3%
Total operating expenses
499,572.0378,023.0333,975.0157,814.0113,433.078,209.0▲13.2%+48.3%
Operating incomefeeds ROC rank
−463,037.0−159,313.0−326,975.0−134,429.0−62,502.0−50,268.0▲51.3%—
Other income, net
44,500.045,615.052,498.021,468.00.0506.0——
Pretax income
−418,537.0−113,698.0−274,477.0−112,961.0−62,502.0−49,762.0▲58.6%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−420,013.0−113,698.0−274,477.0−112,961.0−58,655.0−49,762.0▲58.6%—
Per share
Diluted EPSbuyback-sensitive
−4.46−1.28−3.36−1.96−1.42−1.41▲61.9%—
Diluted shares (mn)
102.9488.4981.6857.5241.4435.25▲8.3%+25.9%
Margins
Gross margin
100.0%100.0%100.0%100.0%100.0%100.0%▲0.0pp+0.0pp
Operating margin
−1267.4%−72.8%−4671.1%−574.9%−122.7%−179.9%▲4598.2pp+107.1pp
Net margin1st pct in Healthcare
−1149.6%−52.0%−3921.1%−483.0%−115.2%−178.1%▲3869.1pp+126.1pp
† TTM = trailing four quarters through 2026-09-30.
FY18 – FY20 · 3 more years
Unlock the full history →
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-17 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Ideaya Biosciences' revenue last fiscal year?

Ideaya Biosciences reported revenue of $218.7M in fiscal 2025, up 3024.4% from fiscal 2024.

What was Ideaya Biosciences' net income?

Ideaya Biosciences reported net income of −$113.7M in fiscal 2025, a net margin of −52.0%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.